Progesterone gel - Juniper Pharmaceuticals

Drug Profile

Progesterone gel - Juniper Pharmaceuticals

Alternative Names: COL-1620; Crinone; Crinone 4%; Crinone 8%; Crinone8%; OneCrinone; Prochieve; Prochieve4%; Prochieve8%; progesterone vaginal gel 4%; progesterone vaginal gel 8%

Latest Information Update: 15 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Columbia Laboratories
  • Developer Actavis; Allergan; Juniper Pharmaceuticals; Merck KGaA
  • Class Hormonal contraceptives; Hormonal replacements; Infertility therapies; Pregnenediones; Small molecules
  • Mechanism of Action Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Amenorrhoea; Dysmenorrhoea; Female infertility; Menopausal syndrome; Menstruation disorders; Premenstrual syndrome
  • Discontinued Preterm labour

Most Recent Events

  • 08 Jan 2018 Juniper Pharmaceuticals extends the duration of its license and supply agreement with Merck KGaA for progesterone gel
  • 18 Sep 2017 Juniper plans to launch progesterone gel in Japan
  • 22 Nov 2016 Juniper and Allergan enter into agreement to monetise future royalty payments for US sales of progesterone gel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top